Welcoming Sihong Zhou as President-Elect of CABS for 2025！
Dear CABS Members, Partners, and Friends,
It is with great pleasure that the Chinese American Biopharmaceutical Society (CABS) announces Sihong Zhou, Senior Scientist at Sutro Biopharma, as our President-Elect for 2025. With over two decades of experience in cancer drug discovery and development and a longstanding commitment to CABS, Sihong is well-prepared to guide the organization toward continued growth and innovation.
Sihong’s distinguished career highlights her expertise in advancing therapeutic candidates from early discovery to clinical development. A graduate of Shanghai Medical University (now Fudan University), she began her career at Chengdu Women and Children’s Hospital, gaining invaluable clinical experience. She later moved to Toronto, Canada, where she spent six years at the Hospital for Sick Children and the University of Toronto.
In 2001, Sihong transitioned to the biopharmaceutical industry, working in key roles at leading organizations such as Genentech, Exelixis, AbbVie, X-Ceptor Therapeutics, Sea Lane Biotechnologies, and Sutro BioPharma. Her extensive knowledge of antibody and small molecule drug development has been instrumental in advancing innovative therapies for patients worldwide.
Beyond her professional accomplishments, Sihong has demonstrated exceptional leadership within CABS. Over the past decade, she has contributed significantly to the organization, serving as Co-Chair of the Operational Office (2020–2023) and Social Life Co-Chair (2015–2019). Her outstanding contributions have been recognized with numerous accolades, including:
-
2014: CABS President’s Outstanding Service Award
-
2015: Outstanding Leadership and Service as SLC Co-Chair
-
2018: Distinguished Leadership and Contribution to CABS
-
2022: Ten Years of Extraordinary Leadership
-
2023: Special Recognition for BioPacific Conference and Anniversary Receptions
Sihong’s dedication to CABS and her remarkable professional journey make her an ideal leader for the next chapter of our organization. Her vision and expertise will ensure CABS continues to thrive as a hub for scientific excellence and global collaboration.
In 2025, Sihong will serve as President-Elect alongside Kay Tong, who will be the President of CABS. Please join me in congratulating both Sihong and Kay on their new roles. We eagerly anticipate a dynamic tenure under their leadership and the continued growth of CABS through the collective efforts of our talented members and volunteers.
Thank you for your continued support and dedication to CABS!
Sincerely,
Jessica Sun, PhD
2024 President of Chinese American Biopharmaceutical Society (CABS)